The Zoetis Catalyst Schedule Wall Street Is Watching

In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Zoetis Inc. ZTS. These include:

• June 25, 2015 - Tax matters agreement with Pfizer expires. ZTS gets more flexibility in selling itself / doing large scale M&A or share buybacks
• April 2015 - Uptake in Apoquel revenues as supply issues expected to be resolved and can launch in new markets
• Mid 2015 - Expected conditional license for a recently filed with USDA new monoclonal Ab for Atopic Dermatitis in dogs (likely to be positioned as 2nd line treatment after Apoquel)
• 2015 - Completion of separating from PFE (rebuilding IT infrastructure - SAP)
• 2015 - Progress of PEDv vaccine launch (protects piglets but sows are vaccinated)
• 2015 - Progress of Improvest/Improvac (pigs) US sales
• 2015-6 - Gradual tax optimization, potential changes in capital structure (more debt)
• 2016 - Monitor sales of Sarolaner - oral anti-tick and flea; see if could be differentiated from competition and market share